Overview

Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine whether it is safe to treat patients with advanced colorectal cancer, with humanised A33 antibody tagged with radioactive iodine (131I-huA33) in combination with chemotherapy (capecitabine).
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig Institute for Cancer Research
Treatments:
Antibodies
Antibodies, Monoclonal
Capecitabine